These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6624563)

  • 1. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
    de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
    Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Excretion of urinary hydroxyproline in urinary tract diseases].
    Guarino A; Comar OB; Taccone W; Cicalese V
    Arch Sci Med (Torino); 1979; 136(2):249-54. PubMed ID: 92978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hydroxyprolinuria in relation to bone metastases in patients with breast cancer].
    Rico Lenza H; Millán Núñez-Cortés J; Rodríguez Mora VI; Espinós Pérez D
    Rev Esp Oncol; 1980; 27(1):61-6. PubMed ID: 7209108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
    Hopkins SC; Nissenkorn I; Palmieri GM; Ikard M; Moinuddin M; Soloway MS
    J Urol; 1983 Feb; 129(2):319-23. PubMed ID: 6834497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
    Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydroxyproline excretion in malignant neoplastic disease.
    Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
    Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
    Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Morphological and histomorphometric study of bone and bone marrow metastases of prostatic adenocarcinoma].
    Cambon C; Pinel B; Le Loët X; Tayot J; Basuyau JP; Deshayes P
    Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):643-50. PubMed ID: 6523015
    [No Abstract]   [Full Text] [Related]  

  • 10. Study of hydroxyproline excretion in patients with prostatic cancer.
    Romics I; Budavári I; Kisbenedek L; Balogh F
    Int Urol Nephrol; 1981; 13(3):275-8. PubMed ID: 7327902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of bone metastases using hydroxyproline excretion].
    Knorr A; Engelmann U; Gross C; Friedrich S
    Radiobiol Radiother (Berl); 1986; 27(1):31-4. PubMed ID: 3704125
    [No Abstract]   [Full Text] [Related]  

  • 12. Urinary hydroxyproline levels in patients with prostatic carcinoma.
    Erol D; Adalar N; Güvençli S; Simşek F
    Int Urol Nephrol; 1983; 15(3):267-70. PubMed ID: 6654633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
    Matsushita Y; Hasegawa K; Sugimura R; Otomo S; Morii H
    Endocrinol Jpn; 1974 Apr; 21(2):109-13. PubMed ID: 4408206
    [No Abstract]   [Full Text] [Related]  

  • 14. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
    Rinsho K; Aoyagi K
    Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer.
    Hopkins SC; Palmieri GM; Niell HB; Moinuddin M; Soloway MS
    Cancer; 1984 Jan; 53(1):117-21. PubMed ID: 6689994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].
    Ditzel J; Jordal R; Riskoer N
    Ugeskr Laeger; 1968 Oct; 130(42):1766-71. PubMed ID: 5724711
    [No Abstract]   [Full Text] [Related]  

  • 17. [Value of the determination of urinary hydroxyproline in the detection of bone metastases].
    Sanz Ortiz J; Mayo Suárez J; Riancho Moral JA; Amado Señarís JA
    Med Clin (Barc); 1983 Sep; 81(7):296-8. PubMed ID: 6645671
    [No Abstract]   [Full Text] [Related]  

  • 18. Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
    Mooppan MM; Wax SH; Kim H; Wang JC; Tobin MS
    J Urol; 1980 May; 123(5):694-6. PubMed ID: 7420557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
    Gasser AB; Jeannet C; Depierre D; Courvoisier B
    Schweiz Med Wochenschr; 1981 Feb; 111(8):246-51. PubMed ID: 7233140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyproline as a marker for following patients with metastatic prostate cancer.
    O'Brien WM; Lynch JH
    J Urol; 1988 Jan; 139(1):66-8. PubMed ID: 3121868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.